Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Allakos Inc. Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria May 28, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports First Quarter 2024 Financial Results May 09, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results March 14, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 February 26, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition February 12, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Announces a Restructuring to Focus on Development of AK006 January 16, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints January 16, 2024 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results November 13, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Appoints Neil Graham to its Board of Directors August 30, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results August 09, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors August 02, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition June 12, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023 June 05, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports First Quarter 2023 Financial Results May 09, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results March 06, 2023 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology November 29, 2022 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting November 10, 2022 From Allakos Inc. Via GlobeNewswire Tickers ALLK Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results November 07, 2022 From Allakos Inc. Via GlobeNewswire Tickers ALLK Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.